Peristomal pyoderma gangrenosum responding to risankizumab

Maximillian A. Weigelt, Robert S. Kirsner

Research output: Contribution to journalArticlepeer-review


Evidence to support available therapies for pyoderma gangrenosum (PG) is limited. Many patients do not respond to topical therapies such as tacrolimus or topical steroids. Currently favored oral systemic treatments (eg, cyclosporine and steroids) achieve complete remission in only 50% of patients and have unfavorable adverse effect profiles. There is a growing body of evidence to support biologic agents for the treatment of PG, but their exact role remains unclear. Here the authors present a patient with peristomal PG, the first reported case of PG responding to treatment with risankizumab, an anti-interleukin 23 monoclonal antibody. Risankizumab may represent an effective and relatively safe treatment for PG that merits additional exploration in prospective, controlled studies.

Original languageEnglish (US)
Pages (from-to)327-329
Number of pages3
JournalAdvances in Skin and Wound Care
Issue number6
StatePublished - 2021
Externally publishedYes


  • adverse effects
  • biologic therapy
  • peristomal
  • pyoderma gangrenosum
  • risankizumab
  • systemic therapy
  • topical therapy

ASJC Scopus subject areas

  • Dermatology
  • Advanced and Specialized Nursing


Dive into the research topics of 'Peristomal pyoderma gangrenosum responding to risankizumab'. Together they form a unique fingerprint.

Cite this